A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors

Transfusion

Volumn 50, Issue 7, 2010, Pages 1513-1523

  Tobler, Leslie H ^a,b,c   Bahrami, Shrein H ^a,b,c   Kaidarova, Zhanna ^a,b,c   Pitina, Lubov ^a,b,c   Winkelman, Valarie K ^a,b,c   Vanderpool, Sandra K ^a,b,c   Guiltinan, Anne M ^a,b,c   Cooper, Stewart ^a,b,c   Busch, Michael P ^a,b,c   Murphy, Edward L ^a,b,c  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b Blood Systems Laboratories   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CHEMICAL ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID ANALYSIS; QUESTIONNAIRE; RISK FACTOR; VIREMIA;

ADULT; AGED; AGED, 80 AND OVER; BLOOD DONORS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RNA, VIRAL; VIREMIA;

EID: 77954340279     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02634.x     Document Type: Article

References (45)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003 362 : 2095 100.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009 29 Suppl 1 : 74 81.
3. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000 20 : 17 35.
4. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006 13 : 34 41.
5. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999 29 : 908 14.
6. Busch MP, Glynn SA, Stramer SL, Orland J, Murphy EL, Wright DJ, Kleinman S NHLBI Retrovirus Epidemiology Donor Study (REDS) Group. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006 46 : 469 75.
7. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003 125 : 80 8.
8. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999 340 : 1228 33.
9. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000 32 : 91 6.
10. Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, Tobler LH, Busch MP, Carrington M, McKeating JA, O'Brien TR, Rehermann B. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008 198 : 203 12.
11. Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV, Cramp ME. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008 198 : 1749 55.
12. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000 40 : 1165 8.
13. Busch MP, Dodd RY. NAT and blood safety: what is the paradigm? Transfusion 2000 40 : 1157 60.
14. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 1995 35 : 903 10.
15. Vermehren J, Kau A, Gartner BC, Göbel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008 46 : 3880 91.
16. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000 343 : 1666 72.
17. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 343 : 1673 80.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65. (Pubitemid 32913521)
19. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000 284 : 450 6.
20. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008 12 : 713 26.
21. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O'Brien SJ, Karacki P, Marti D, Astemborski J, Carrington M. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001 184 : 16 21.
22. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004 305 : 872 4.
23. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, Wright M, Chiaramonte M, Graves M, Thomas HC, Hill AV, Thursz MR. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003 4 : 411 9.
24. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009.
25. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5 : 215 29.
26. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. Analysis of a successful immune response against hepatitis C virus. Immunity 1999 10 : 439 49.
27. Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP. Viral and host factors in early hepatitis C virus infection. Hepatology 2005 42 : 86 92. (Pubitemid 40911315)
28. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Protection against persistence of hepatitis C. Lancet 2002 359 : 1478 83.
29. von Dossow V, Sander M, MacGill M, Spies C. Perioperative cell-mediated immune response. Front Biosci 2008 13 : 3676 84.
30. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005 5 : 558 67.
31. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 : 825 32.
32. Kleinman S, Wang B, Wu Y, Glynn SA, Williams A, Nass C, Ownby H, Busch MP Retrovirus Epidemiology Donor Study. The donor notification process from the donor's perspective. Transfusion 2004 44 : 658 66.
33. Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006 101 : 2360 78.
34. Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, Kaldor JM, van Beek I, Dore GJ. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004 190 : 1270 4.
35. Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, Binelli G, Donato F, Zanetti AR, Podda M, Tagger A. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002 36 : 993 1000.
36. Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, Dockter J, Giachetti C, Seeff LB, Busch MP Transfusion-transmitted Viruses Study and Retrovirus Epidemiology Donor Study Groups. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008 15 : 120 8.
37. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005 45 : 994 1002. (Pubitemid 40798792)
38. Rugege-Hakiza SE, Glynn SA, Hutching ST, Bethel J, Nass CC, McEntire RL, Hirschler NV, Campbell JG, Ladavac A, Schreiber GB Retrovirus Epidemiology Donor Study. Do blood donors read and understand screening educational materials? Transfusion 2003 43 : 1075 83.
39. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A, Rosen HR. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007 196 : 1474 82.
40. Alric L, Fort M, Izopet J, Vinel JP, Bureau C, Sandre K, Charlet JP, Beraud M, Abbal M, Duffaut M. Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens 2000 56 : 154 8.
41. Inoue G, Horiike N, Michitaka K, Onji M. Hepatitis C virus clearance is prominent in women in an endemic area. J Gastroenterol Hepatol 2000 15 : 1054 8.
42. Yamakawa Y, Sata M, Suzuki H, Noguchi S, Tanikawa K. Higher elimination rate of hepatitis C virus among women. J Viral Hepat 1996 3 : 317 21.
43. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006 55 : 1183 7.
44. Stroffolini T, Rapicetta M, Di Stefano R. Hepatitis C virus clearance and gender. Gut 2007 56 : 884 author reply.
45. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med 2009 360 : 1902 6.